Business Description
Axonics Inc
NAICS : 334510
SIC : 3841
ISIN : US05465P1012
Description
Axonics Inc is a United States-based medical technology company. It focuses on developing and commercializing novel products for adults with bladder and bowel dysfunction, that include implantable SNM systems to treat urinary urge incontinence and urinary urgency frequency (UUF); a urethral bulking agent (Bulkamid) to treat female stress urinary incontinence. SNM therapy is predominantly used to treat patients with overactive bladder, fecal incontinence, and urinary retention. Geographically, the company generates majority of its revenue from United States and rest from International markets.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 10.53 | |||||
| Equity-to-Asset | 0.88 | |||||
| Debt-to-Equity | 0.05 | |||||
| Debt-to-EBITDA | 3.22 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 23.92 | |||||
| Beneish M-Score | -2.05 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 35.3 | |||||
| 3-Year FCF Growth Rate | 63.6 | |||||
| 3-Year Book Growth Rate | 20.4 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 85.85 | |||||
| Future 3-5Y Total Revenue Growth Rate | 19.7 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 40.58 | |||||
| 9-Day RSI | 44.66 | |||||
| 14-Day RSI | 46.37 | |||||
| 6-1 Month Momentum % | 15.53 | |||||
| 12-1 Month Momentum % | 34.01 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 9.96 | |||||
| Quick Ratio | 8.04 | |||||
| Cash Ratio | 6.88 | |||||
| Days Inventory | 292.66 | |||||
| Days Sales Outstanding | 46.08 | |||||
| Days Payable | 57.75 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -8.3 | |||||
| Shareholder Yield % | -0.2 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 75.25 | |||||
| Operating Margin % | -1.93 | |||||
| Net Margin % | -4.12 | |||||
| FCF Margin % | -4.16 | |||||
| ROE % | -2.61 | |||||
| ROA % | -2.34 | |||||
| ROIC % | -2.7 | |||||
| ROC (Joel Greenblatt) % | -3.1 | |||||
| ROCE % | -0.48 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 625.44 | |||||
| PE Ratio without NRI | 714.84 | |||||
| PS Ratio | 8.71 | |||||
| PB Ratio | 5.52 | |||||
| Price-to-Tangible-Book | 7.7 | |||||
| EV-to-EBIT | -1038.22 | |||||
| EV-to-EBITDA | 322.51 | |||||
| EV-to-Forward-EBITDA | -59.45 | |||||
| EV-to-Revenue | 8.17 | |||||
| EV-to-Forward-Revenue | 6.95 | |||||
| EV-to-FCF | -194.24 | |||||
| Price-to-Projected-FCF | 38.49 | |||||
| Price-to-Graham-Number | 15.64 | |||||
| Price-to-Net-Current-Asset-Value | 8.81 | |||||
| Price-to-Net-Cash | 14.16 | |||||
| Earnings Yield (Greenblatt) % | -0.1 | |||||
| FCF Yield % | -0.47 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers